Raytheon awarded $71 million in Navy contracts for missile systems
NEW YORK - SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), a small-cap biotech with a market capitalization of $170.62 million, will be added to the Russell 3000 and Russell 2000 Indexes effective after market close on June 27, as part of the 2025 Russell indexes annual reconstitution. The stock has shown remarkable momentum, gaining over 83% in the past six months according to InvestingPro data.
The Russell 3000 Index tracks the performance of the 3,000 largest publicly traded U.S. companies and serves as a benchmark for the U.S. equity market. The Russell 2000 Index, a subset of the Russell 3000, measures small-cap stock performance and represents approximately 10% of the total market capitalization of the U.S. equity market.
Membership in these indexes lasts for one year and includes automatic inclusion in appropriate growth and value style indexes. The Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.
"Being added to the Russell 3000 and Russell 2000 Indexes marks an important corporate milestone for SELLAS and reflects the strong progress we continue to make advancing our pipeline and building long-term shareholder value," said John Burns, Senior Vice President and Chief Financial Officer of SELLAS, in a press release statement.
SELLAS is a late-stage clinical biopharmaceutical company focused on developing therapies for various cancer indications. The company is currently awaiting full topline Phase 2 data of its SLS009 treatment for acute myeloid leukemia (AML) and the final analysis of its Phase 3 pivotal REGAL trial of GPS in AML.
Information about the inclusion was provided in a company press release issued Tuesday.
In other recent news, SELLAS Life Sciences Group, Inc. has reported significant developments regarding its cancer therapy programs. The company released data from its Phase 2 trial of SLS009, showing a median overall survival of 8.9 months in patients with acute myeloid leukemia (AML) with myelodysplasia-related changes. This outcome surpasses the historical benchmark of 2.5 months for similar patient profiles. Additionally, SELLAS presented promising preclinical data for SLS009 at the ASCO Annual Meeting, highlighting its efficacy in colorectal cancer cell lines with ASXL1 mutations.
In another development, SELLAS has initiated treatment for the first pediatric patient in a Phase 2 trial of SLS009 for relapsed/refractory AML. The trial aims to evaluate the safety and efficacy of SLS009 in combination with venetoclax and azacitidine. Furthermore, the company has expanded its Scientific Advisory Board with the addition of oncology experts Philip C. Amrein, MD, and Alex Kentsis, MD, PhD, to advance its clinical programs. SELLAS continues to focus on developing novel therapeutics, with its lead product candidate GPS targeting the WT1 protein in various tumor types. These recent advancements reflect SELLAS’s ongoing efforts in oncology drug development.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.